Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Nanobody-based Naturally Selected CD7-Targeted CAR-T Therapy for Acute Myeloid Leukemia

Peihua Lu, Xian Zhang, Junfang Yang, Jingjing Li, Liyuan Qiu, Meiwei Gong, Hui Wang, Jiaqi Chen, Hongxing Liu, Min Xiong, Ying Liu, Lin Wang

Blood blood.2024024861.

https://doi.org/10.1182/blood.2024024861

Published: 2024

Includes: Supplemental data

Journal Articles

CD7-Targeted CAR-T Cell Therapy Shows Promising Efficacy and Safety in Treating Refractory/Relapsed Peripheral T-Cell Lymphoma: Phase I Clinical Trial

Junfang Yang, Xian Zhang, Jingjing Li, Liyuan Qiu, Lin Wang, Peihua Lu

Blood (2024) 144 (Supplement 1): 2075.

https://doi.org/10.1182/blood-2024-196853

Published: 2024

Journal Articles

Naturally Selected CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Acute Myeloid Leukemia: Phase I Clinical Trial

Xian Zhang, Junfang Yang, Jingjing Li, Liyuan Qiu, Hongxing Liu, Sr., Min Xiong, Jianqiang Li, Peihua Lu

Blood (2023) 142 (Supplement 1): 218.

https://doi.org/10.1182/blood-2023-179086

Published: 2023

Journal Articles

High Efficacy and Safety of Nanobody Based Anti-BCMA CAR-T Cell Therapy in Treating Patients with Relapsed or Refractory Multiple Myeloma

Xian Zhang, Lin Wang, Junfang Yang, Jingjing Li, Hongxing Liu, Jianqiang Li, Peihua Lu

Blood (2023) 142 (Supplement 1): 2107.

https://doi.org/10.1182/blood-2023-185271

Published: 2023

Journal Articles

Comparative Analysis of Immune Effector Cell-Associated Hematotoxicity (ICAHT) and Infection Incidence Following CD19-Targeted CAR-T Therapy Versus CD7-Targeted CAR-T Therapy

Xian Zhang, Qinglong Wang, Ying Liu, Junfang Yang, Jingjing Li, Hongxing Liu, Jianqiang Li, Peihua Lu

Blood (2023) 142 (Supplement 1): 6883.

https://doi.org/10.1182/blood-2023-185361

Published: 2023

Journal Articles

A novel RIPK1 inhibitor reduces GVHD in mice via a nonimmunosuppressive mechanism that restores intestinal homeostasis

Blood (2023) 141 (9): 1070–1086.

https://doi.org/10.1182/blood.2022017262

Published: 2023

Includes: Supplemental data

Journal Articles

Analysis of 53 Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) Treated with CD7-Targeted CAR-T Cell Therapy

Xian Zhang, Junfang Yang, Jingjing Li, Liyuan Qiu, Jianqiang Li, Peihua Lu

Blood (2022) 140 (Supplement 1): 2369–2370.

https://doi.org/10.1182/blood-2022-158878

Published: 2022

Journal Articles

The Efficacy of Chidamide Maintenance Therapy after CAR-T Therapy for Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia

Xian Zhang, Lefu Huang, Gailing Zhang, Yunchao Su, Xiaona Hu, Shulian Xia, Jingjing Li, Peihua Lu

Blood (2022) 140 (Supplement 1): 8884–8885.

https://doi.org/10.1182/blood-2022-168603

Published: 2022

Journal Articles

A Novel Universal CD7-Targeted CAR-T Cell Therapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia and T-Cell Lymphoblastic Lymphoma

Xian Zhang, Yali Zhou, Junfang Yang, Jingjing Li, Liyuan Qiu, Wengang Ge, Bo Pei, Jie Chen, Lu Han, Jiangtao Ren, Peihua Lu

Blood (2022) 140 (Supplement 1): 4566–4567.

https://doi.org/10.1182/blood-2022-165733

Published: 2022

Journal Articles

Factors Associated with Outcomes Among Refractory/Relapsed TP53-Mutated/Chromosome 17p Deletion Acute B-Cell Lymphoblastic Leukemia (B-ALL) Patients Treated with CD19-Targeted Chimeric Antigen Receptor (CAR)-T Therapy

Xian Zhang, Gailing Zhang, Wenqian Li, Yang Zhang, Tong Wang, Junfang Yang, Jingjing Li, Peihua Lu

Blood (2021) 138 (Supplement 1): 3828.

https://doi.org/10.1182/blood-2021-149809

Published: 2021

Journal Articles

Evolution and Proliferation of CD7 CAR-T Cells Compared to CD19 CAR-T Cells Therapies for Acute Leukemia

Xian Zhang, Gailing Zhang, Wenqian Li, Liyuan Qiu, Dongchu Wang, Junfang Yang, Jingjing Li, Peihua Lu

Blood (2021) 138 (Supplement 1): 2820.

https://doi.org/10.1182/blood-2021-149978

Published: 2021

Journal Articles

First-in-Human Clinical Study of a Novel CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Mixed Phenotype Acute Leukemia (MPAL)

Xian Zhang, Junfang Yang, Jingjing Li, Yanze Shi, Yunchao Su, Ying Liu, Min Ba, Yan Wu, Wenqian Li, Jianqiang Li, Peihua Lu

Blood (2021) 138 (Supplement 1): 1741.

https://doi.org/10.1182/blood-2021-146425

Published: 2021

Journal Articles

Factors Predicting Long-Term Survival Following CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Xian Zhang, MD, Junfang Yang, Wenqian Li, Gailing Zhang, MD, Yunchao Su, Yanze Shi, Dan Song, Min Zhang, Jiujiang He, Li Xu, Jingjing Li, Xinan Lu, Jianqiang Li, PhD, Xiangqun Li, Zhongwei Xu, Ziyu Li, Peihua Lu, MD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-136897

Published: 2020

Journal Articles

A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL)

Xian Zhang, MD, Jiasheng Wang, Yue Liu, Junfang Yang, Jingjing Li, Gailing Zhang, MD, Yanze Shi, Jiujiang He, Dan Song, Wenqian Li, Shulian Xia, Min Zhang, Zhixiao Zhou, Lemei Jia, Hongli Zheng, Xin Lin, Peihua Lu, MD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-136833

Published: 2020

Journal Articles

Successful 24-Hours Manufacture of Anti-CD19/CD22 Dual Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Junfang Yang, Pengfei Jiang, Xian Zhang, MD, Jingjing Li, Yan Wu, Li Xu, Yunchao Su, Xiaona Hu, Xiaoyan Zhao, Qi Dong, Songbai Cai, Zhenguang Wang, Yuezhang Chen, Xun Ye, Jiaping He, Nanjing Lin, Wei Cao, Martina Sersch, MD PhD, Peihua Lu, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-136866

Published: 2020

Journal Articles

Feasibility, and Efficacy of Donor-Derived cd19-Targeted Car t-Cell Therapy in Refractory/Relapsed(r/r)b-Cell Acute Lymphoblastic Leukemia (b-all) Patients

Xian Zhang, MD, Junfang Yang, Wenqian Li, Gailing Zhang, MD, Yunchao Su, Yanze Shi, Dan Song, Min Zhang, Jiujiang He, Li Xu, Liyuan Qiu, Xin-An Lu, Fei Wu, Jianqiang Li, PhD, Dandan Chen, Xiangqun Li, Ziyu Li, Jingjing Li, Peihua Lu, MD

Blood (2020) 136 (Supplement 1): 4–6.

https://doi.org/10.1182/blood-2020-137299

Published: 2020

Journal Articles

Significant Long-Term Benefits of CAR T-Cell Therapy Followed By a Second Allo-HSCT for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Who Relapsed after an Initial Transplant

Jianping Zhang, Junfang Yang, Xian Zhang, MD, Jingjing Li, Xingyu Cao, Yanli Zhao, Zhijie Wei, Deyan Liu, Min Xiong, Yue Lu, Jiarui Zhou, Ruijuan Sun, Peihua Lu, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-136014

Published: 2020

Journal Articles

Anti-CD19/CD22 Dual CAR-T Therapy for Refractory and Relapsed B-Cell Acute Lymphoblastic Leukemia

Junfang Yang, MD, Pengfei Jiang, Xian Zhang, MD, Xiaobin Zhu, Qi Dong, Jiaping He, Nanjing Lin, Zhenguang Wang, Songbai Cai, Xun Ye, Yunchao Su, Wenqian Li, Jingjing Li, Ziyao Yu, Jiujiang He, Li Xu, Dan Song, Wei Cao, Peihua Lu

Blood (2019) 134 (Supplement_1): 284.

https://doi.org/10.1182/blood-2019-126429

Published: 2019

Journal Articles

Analysis of Factors Predicting Treatment Response of 254 Patients Who Received CD19-Targeted CAR-T Cell Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Xian Zhang, MD, Junfang Yang, MD, Yanze Shi, Dan Song, Jingjing Li, Xin-an Lu, PhD, Fei Wu, Jianqiang Li, Ph. D., Dandan Chen, Xiangqun Li, Zhongwei Xu, Shuqiang Liu, Ziyu Li, Kui YIng, Wenya Wang, Peihua Lu

Blood (2019) 134 (Supplement_1): 224.

https://doi.org/10.1182/blood-2019-125503

Published: 2019

Journal Articles

A Feasibility and Safety Study of a New CD19-Directed Fast CAR-T Therapy for Refractory and Relapsed B Cell Acute Lymphoblastic Leukemia

Blood (2019) 134 (Supplement_1): 825.

https://doi.org/10.1182/blood-2019-121751

Published: 2019

NARROW

Nanobody-based Naturally Selected CD7-Targeted CAR-T Therapy for Acute Myeloid Leukemia

CD7-Targeted CAR-T Cell Therapy Shows Promising Efficacy and Safety in Treating Refractory/Relapsed Peripheral T-Cell Lymphoma: Phase I Clinical Trial

Naturally Selected CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Acute Myeloid Leukemia: Phase I Clinical Trial

High Efficacy and Safety of Nanobody Based Anti-BCMA CAR-T Cell Therapy in Treating Patients with Relapsed or Refractory Multiple Myeloma

Comparative Analysis of Immune Effector Cell-Associated Hematotoxicity (ICAHT) and Infection Incidence Following CD19-Targeted CAR-T Therapy Versus CD7-Targeted CAR-T Therapy

A novel RIPK1 inhibitor reduces GVHD in mice via a nonimmunosuppressive mechanism that restores intestinal homeostasis

Analysis of 53 Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) Treated with CD7-Targeted CAR-T Cell Therapy

The Efficacy of Chidamide Maintenance Therapy after CAR-T Therapy for Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia

A Novel Universal CD7-Targeted CAR-T Cell Therapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia and T-Cell Lymphoblastic Lymphoma

Factors Associated with Outcomes Among Refractory/Relapsed TP53-Mutated/Chromosome 17p Deletion Acute B-Cell Lymphoblastic Leukemia (B-ALL) Patients Treated with CD19-Targeted Chimeric Antigen Receptor (CAR)-T Therapy

Evolution and Proliferation of CD7 CAR-T Cells Compared to CD19 CAR-T Cells Therapies for Acute Leukemia

First-in-Human Clinical Study of a Novel CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Mixed Phenotype Acute Leukemia (MPAL)

Factors Predicting Long-Term Survival Following CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL)

Successful 24-Hours Manufacture of Anti-CD19/CD22 Dual Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Feasibility, and Efficacy of Donor-Derived cd19-Targeted Car t-Cell Therapy in Refractory/Relapsed(r/r)b-Cell Acute Lymphoblastic Leukemia (b-all) Patients

Significant Long-Term Benefits of CAR T-Cell Therapy Followed By a Second Allo-HSCT for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Who Relapsed after an Initial Transplant

Anti-CD19/CD22 Dual CAR-T Therapy for Refractory and Relapsed B-Cell Acute Lymphoblastic Leukemia

Analysis of Factors Predicting Treatment Response of 254 Patients Who Received CD19-Targeted CAR-T Cell Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)

A Feasibility and Safety Study of a New CD19-Directed Fast CAR-T Therapy for Refractory and Relapsed B Cell Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only